title: Predictive factors of response to treatment in patients with metastatic renal cell carcinoma: new evidence.
abstract: Renal cell carcinoma represents approximately 3% of adult malignancies and 90-95% of neoplasms arising from the kidney. Many agents that target angiogenesis (e.g., sunitinib, sorafenib, bevacizumab and pazopanib) and mTOR-targeted therapy (e.g., temsirolimus and everolimus) have been approved as first-line agents. The choice of the most suitable treatment for advanced renal cell carcinoma depends on the definition of risk. In this article, we reviewed the scientific literature identifying predictive factors on the activity/efficacy of a specific therapy.
authors.affiliation: Department of Medical Oncology, University Campus Bio-Medico, Via Alvaro del Portillo, 200 00128 Rome, Italy. g.tonini@unicampus.it
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Tonini
authors.forename: Maria Elisabetta
authors.initials: ME
authors.lastname: Fratto
authors.forename: Marco
authors.initials: M
authors.lastname: Imperatori
authors.forename: Francesco
authors.initials: F
authors.lastname: Pantano
authors.forename: Bruno
authors.initials: B
authors.lastname: Vincenzi
authors.forename: Daniele
authors.initials: D
authors.lastname: Santini
mesh_terms: D000328:Adult; D020533:Angiogenesis Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000473:pathology; D016503:Drug Delivery Systems; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000473:pathology; D012306:Risk; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors; D016896:Treatment Outcome
chemical_list: D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; C546842:MTOR protein, human; D058570:TOR Serine-Threonine Kinases